In vitro assessment of the potency of some Newcastle disease vaccine brands in Ibadan, Nigeria by Okanlawon, A.A. et al.




Okanlawon et al. Afr. J. Clin. Exper. Microbiol. 2020; 21 (4): 328 – 332                                                         https://www.afrjcem.org 
African Journal of Clinical and Experimental Microbiology. ISSN 1595-689X                                                   Oct 2020; Vol.21 No.4                                                                                              
AJCEM/2001. https://www.ajol.info/index.php/ajcem                                              
Copyright AJCEM 2020: https://doi.org/10.4314/ajcem.v21i4.9                                        
Original Article                                                                        Open Access 
In vitro assessment of the potency of some Newcastle disease 
vaccine brands in Ibadan, Nigeria 
 
1Okanlawon, A. A., *2Ameen, S. A., 2Kadir, R. A., 2Ambali, H. M., 2Baba, Y. A., 3Azeez, O. M. 
and 4Owoade, A. A. 
 
1Veterinary Diagnostic Laboratory for Poultry and Livestock Diseases, CHI Farms Ltd, Ibadan, Nigeria 
2Department of Veterinary Medicine, University of Ilorin, Nigeria 
3Department of Physiology and Biochemistry, University of Ilorin, Nigeria 
                                             4Department of Veterinary Medicine, University of Ibadan, Nigeria 
*Correspondence to: drsaameen@yahoo.com; ameen.sa@unilorin.edu.ng; +2348125064091;                                         




Background: Newcastle disease (ND) is a very common and economically important disease of poultry. There is no 
drug for treatment of the disease during an outbreak in poultry flocks, and prevention by vaccination is one of the 
recommended control measures. However, post vaccination outbreaks have been observed on many occasions in 
chicken flocks and one of the causes has been attributed to possible failure of vaccine to confer immunity. This 
study was designed to evaluate the potency of ND vaccines available in Ibadan, Nigeria.  
Methodology: Haemagglutination (HA) technique and elution phenomenon were employed to evaluate the potency 
of ND vaccines randomly selected in Ibadan. A total of 45 vaccines comprising 9 brands and 5 different strains were 
selected for potency test. The vaccine brands included ‘Vireo 116’ (n=10), ‘ABIC’ (n=5), ‘Biovac’(n=9), 
‘Nobilis’(n=3), ‘NVRI’(n=12), ‘R2B’ (n=2), ‘BAL-ND’ (n=2), ‘Forte dodge’(n=1) and ‘Jovac’ (n=1), while the vaccine 
strains in the brands included Lasota, B1, Clone, Komarov, Hitcher, and an unknown strain.  
Results: Thirty-five of the 45 (77.8%) ND vaccines tested had more than 4 HA titer (>64) and were therefore 
regarded as potent. All the 15 (100%) ND Lasota vaccine strain, 7 out of 10 (70%) ND Komarov strain, 4 out of 5 
(80%) ND clone and 5 out of 8 (62.5%) ND B1 strains were potent. None of the ND brand ‘R2B’ vaccine as well as 
Hitchner strain from ‘Nobilis’ brand was potent, but all 5, 2, 1 and 1 vaccines tested from brands ‘ABIC’, ‘BAL-ND’, 
‘Fort dodge’ and ‘Jovac’ respectively were potent. Similarly, 9 of 10, 6 of 9, 2 of 3 and 9 of 12 vaccine strains tested 
from brands ‘Vireo 116’, ‘Biovac’, ‘Nobilis’ and ‘NVRI’ were respectively potent                       
Conclusion: The occurrence of ND vaccines that are not potent in this study may be contributing to post 
vaccination failure. It is advisable to subject vaccines to potency test before use.  
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Abstrait: 
Contexte: La maladie de Newcastle (ND) est une maladie très courante et économiquement importante des 
volailles. Il n'existe aucun médicament pour le traitement de la maladie lors d'une épidémie dans des troupeaux de 
volailles, et la prévention par vaccination est l'une des mesures de contrôle recommandées. Cependant, des 
flambées post-vaccination ont été observées à de nombreuses reprises dans des troupeaux de poulets et l'une des 
causes a été attribuée à un éventuel échec du vaccin à conférer l'immunité. Cette étude a été conçue pour évaluer 
la puissance des vaccins contre la MN disponibles à Ibadan, au Nigéria.                     
Méthodologie: La technique d'hémagglutination (HA) et le phénomène d'élution ont été utilisés pour évaluer la 
puissance des vaccins contre la MN sélectionnés au hasard à Ibadan. Un total de 45 vaccins comprenant 9 marques 
et 5 souches différentes ont été sélectionnés pour le test d'activité. Les marques de vaccins comprenaient 'Vireo 
116' (n=10), 'ABIC' (n=5), 'Biovac' (n=9), 'Nobilis' (n=3), 'NVRI' (n=12), 'R2B' (n=2), 'BAL-ND' (n=2), 'Forte 
dodge' (n=1) et 'Jovac' (n=1), tandis que les souches vaccinales des marques comprenaient Lasota, B1, Clone, 
Komarov, Hitcher et une souche inconnue.                                            
Résultats: Trente-cinq des 45 vaccins contre la MN testés (77,8%) avaient plus de 4 titres en HA (>64) et étaient 
donc considérés comme puissants. Toutes les 15 (100%) souches de vaccin ND Lasota, 7 souches sur 10 (70%) ND 
Komarov, 4 sur 5 (80%) clones ND et 5 sur 8 (62,5%) souches ND B1 étaient puissantes. Aucun des vaccins ’R2B’ 
de marque ND ni la souche Hitchner de la marque ’Nobilis’ n'étaient puissants, mais tous les vaccins 5, 2, 1 et 1 
testés des marques ‘ABIC’, ‘BAL-ND’, ‘Fort dodge’ et ‘Jovac’ respectivement était puissant. De même, 9 des 10, 6 
des 9, 2 des 3 et 9 des 12 souches vaccinales testées des marques ’Vireo 116’, ‘Biovac’, ‘Nobilis’ et ‘NVRI’ étaient 
respectivement puissantes                            
Conclusion: La présence de vaccins contre la MN qui ne sont pas puissants dans cette étude peut contribuer à 
l'échec post-vaccinal. Il est conseillé de soumettre les vaccins à un test de puissance avant utilisation. 
Mots-clés: in vitro, évaluation, puissance, maladie de Newcastle, marques de vaccin, souches vaccinales 
Introduction: 
 
 Newcastle disease (ND) is a highly 
contagious viral disease of domestic and wild 
birds. The disease is caused by the Newcastle 
disease virus (NDV) of the avian paramyxo- 
virus 1 (APMV-1), a single-stranded, negative-
sense ribonucleic acid (-ssRNA) virus belonging 
to the family Paramyxovirdae, sub-family Para- 
myxovirinae and genus Rubulavirus (1,2,3). 
The virus exhibits hemagglutinin/neuramini- 
dase (HN) and fusion (F) glycoprotein spikes at 
its surface (2,4). These proteins are important 
in determining the virulence and infectivity of 
the virus (2). Also, the hemagglutination pro- 
perty is an important aid in the laboratory for 
virus detection by hemagglutination test (5).  
 Newcastle disease was first recognized 
in Indonesia and England in 1926 (6), though 
earlier existence of the disease dating back to 
the mid 19th century had been postulated (7). 
Since then it has become worldwide in distri- 
bution (2). It was first reported in Nigeria in 
1951 with laboratory confirmation in 1953 (8). 
Since its recognition, the disease has been 
regarded as endemic in Nigeria. The disease 
shave been reported as the most important 
viral disease of poultry in the world (9), and a 
major constraint to the poultry industry in 
Nigeria and Africa in general (9,10), in which it 
can cause devastating losses in both comm- 
ercial and village chickens (11).  
 The disease is characterized by diges- 
tive, respiratory and/or nervous signs. The 
disease has a number of strains that differ in 
the severity of their clinical signs, ranging from 
in apparent infection to a rapidly fatal condition 
(2,6,12). There are many ND vaccines suitable 
for use in commercial poultry, many of which 
are available in Nigeria. However, these 
vaccines can be broadly grouped into two; the 
first are live/attenuated ND vaccines which are 
vaccines made with strains of virus of low to 
moderate virulence that are able to infect cell, 
but have been substantially modified to lose 
pathogenicity while maintaining immunogeni- 
city. They are given by intraocular, intra- 
nasal, oral and intramuscular routes, and they 
mirror natural infection and induce cell 
mediated, humoral and local immunity. The 
second are killed/inactivated ND vaccines, 
which are inactivated organisms usually com- 
bined with an oil emulsion or aluminium 
hydroxide adjuvant. They are usually admini- 
stered to individual birds by intramuscular or 
subcutaneous injection, and mainly elicit hum- 




oural immunity (5,13).  
 It has been reported that procedure for 
the production of ND vaccine may differ from 
one producer to the other in terms of cultures 
and degree of passage. While some use cell 
culture for propagation, others may use 
chicken embryo. Some producers may have 
short passage while others may perform long 
passage for vaccine seed attenuation, and this 
may have effect on potency of the resulting 
vaccine. From literature on ND vaccines, it has 
been observed that titres of infective dose vary 
from one brand to the other, which again could 
have effect on the potency of the vaccine. 
Fluctuations in storage temperature of vaccines 
may also have deleterious effect on vaccine 
potency. In view of unstable electricity power 
supply in Nigeria, it is most appropriate to 
investigate how potent are vaccines sold at 
various outlets in Ibadan. ND outbreaks in 
vaccinated flocks are common occurrence in 
poultry flocks and the causes of such vaccine 
failure are many, one of which is lack or loss of 
potency of vaccine. This study was designed to 
determine the potency of selected ND vaccines 
available to poultry farmers at the point of 
purchase in Ibadan. 
 
Materials and method: 
 
Study setting 
 The study was carried out at the 
Biotechnology Laboratory of the Department of 
Veterinary Medicine, University of Ibadan. 
 
Sources of vaccines and materials for testing 
 Newcastle disease vaccines (a total of 
45 vaccines with 9 brands and 5 known 
strains) were randomly obtained from National 
Veterinary Research Institute branch office at 
Mokola, Ibadan, Nigeria, and from private 
veterinary shops and clinics where poultry 
vaccines are sold. The materials used included 
samples of nine brands of ND vaccines, 
phosphate buffered solution (PBS) tablets, 
Chicken red blood cells (Crbc), 50µl single and 
8-channel pipette, distilled water, and U-
bottom microtitre plates. 
 
Determination of haemagglutination (HA) titre 
 First, 0.5% of washed Chicken RBC 
(Crbc) was prepared in PBS. Then, each 
vaccine was diluted with PBS to give 250 doses 
per ml of PBS. The wells (1-12) in rows of the 
microtitre plates were filled with 50µl of PBS 
and 50µl of the diluted vaccine was added to 
the PBS in the first well (well 1) in the row and 
diluted serially up to well 11. Well 12 served as 
negative control. 50µl of 0.5% Crbc was then 
added to each well 1 to 12. The reaction was 
allowed to continue until Crbc in the control 
well 12 completely settles (buttoning). Haema- 
gglutination titre was taken as the reciprocal of 
the dilution number of last well to show 100% 
haemagglutination (complete carpeting of well 
by red blood cells). Each vaccine was tested in 
triplicate. 
 
Haemagglutination inhibition test 
 Vaccines that showed haemagglutina- 
tion were reacted with standard serum contain- 
ing ND antibodies obtained from chicken chall- 
enged with ND vaccine. Inhibition of the haem- 
agglutination was shown by settling of Crbc  
 
Interpretation of results 
 Observation of complete haemagglut- 
ination indicated presence of potent haem- 
agglutinating substance in the vaccine, and the 
haemagglutination titer indicated potency of 
the vaccine. Inhibition of the haemagglutina- 




 The last well to show haemaggluti- 
nation for each vaccine brand during the 
haemagglutination test was observed for the 
period of time it takes for the Crbc to settle. 
Any vaccine in which haemagglutination disap- 
pears, resulting in Crbc settling, has elution. 
Any vaccine without elution after 30 minutes 
was regarded as potent and the shorter the 





 A total of 45 ND vaccines were tested 
from the 9 vaccine brands (Nos 1-9), 35 of 
which belong to 5 different vaccine strains 
(Lasota, B1, Clone, Komarov and Hitcher) while 
6 were unknown vaccine strain (Table 1). 
Thirty-five of the 45 (77.8%) ND vaccines 
tested had more than 4 HA titer (>64) and 
were therefore  regarded  as  potent. All 15 ND 














1 Vireo 116: 
(n=10) 
     
Lasota 512, 128 and 1025 100 None Very potent 
B1 64, 512 50 Yes (1/2) Fairly potent 
Lasota 512, 256, 512, 256 and 
512 
100  Very potent 
2 ABIC: 
(n=5) 
     
B1 2048, 128 and 128 100 Yes (1/3) Potent 
Lasota 128 and 128 100  Potent 
3 Biovac: 
(n=9) 
     
B1 0, 2 and 256 33.3  Barely potent 
Clone 512, 256, 2048 and 64 75  Potent 
Lasota 128 and 128 100  Potent 
4 Nobilis 
(n=3) 
     
Hitchner 2 0  Not potent 
Lasota 256 100  Potent 
Clone 256 100  Potent 
5 N.V.R.I (Vom): 
(n=12) 
     
Komarov 256, 256, 640, 128, 256, 
16, 64, 16, 512, and 512 
70  Fairly potent 
Lasota 256 and 1024 100  Potent 
6 R2B: 
(n=2) 
Not known 0 and 8 0 Yes Not potent 
7 BAL-ND: 
(n=2) 
Not known 128 and 512 100  Potent 
8 Fort dodge: 
(n=1) 
Not known 512 100  Potent 
9 Jovac: 
(n=1) 
Not known 1024 100  Potent 
n = number of vaccines tested 
 
Lasota (100%), 7 out of 10 ND Komarov 
(70%), 4 out of 5 ND clone (80%) and 5 out of 
8 ND B1 strains (62.5%) were potent. None of 
the ND brand ‘R2B’ vaccine as well as Hitchner 
from ‘Nobilis’ brand was potent, but all 5, 2, 1 
and 1 vaccines tested from brands ‘ABIC’, 
‘BAL-ND’, ‘Fort dodge’ and ‘Jovac’ respectively 
were potent. Similarly, 9 of 10, 6 of 9, 2 of 3 
and 9 of 12 vaccines tested from brands ‘Vireo 
116’, ‘Biovac’, ‘Nobilis’ and ‘NVRI’ were 




 In Nigeria and elsewhere, live and 
inactivated vaccines are routinely used in the 
prevention of Newcastle disease (14). New- 
castle disease vaccines are produced by differ- 
rent manufacturers which are sold to veteri- 
narians under different brand names. The 
number of vaccines tested in this study is a 
reflection of the availability of each brand of 
vaccine and may also be a reflection of their 
popularity, the locally produced vaccine ‘NVRI’ 
(26.7%) being the most readily available, 
followed by ‘Vireo 116’ (22.2%) and ‘Biovac’ 
(20%) brands. The use of HA technique for 
evaluation of ND vaccine potency is well 
established (15,16). Ten of the 45 vaccines 
(22.2%) tested were not potent, having 4 HA 
titer or less. The use of such vaccine flocks will 
result in vaccine failure with consequent risk of 
ND outbreak.  
 All ND vaccine Lasota and clone strains 
tested (100%), 8 of 10 (80%) ND vaccine 
Komarov strain and 5 of 8 (62.5%) ND vaccine 
B1 strains were potent but none of two of the 
‘R2B’ brand of Komarov strain equivalent was 
potent. Therefore, in terms of potency reliab- 
ility, ND vaccine Lasota and clone strains are 
most reliable. In view of the fact that some of 
the other strains are not potent, it will be 
advisable to subject these to potency test 
before use.     
 With regard to performance of brands, 
all strains of ND vaccines of brands ‘Vireo 116’ 
and ‘ABIC’ were potent and therefore are the 
best brands of choice followed by brand of 
‘NVRI’, which is a local vaccine. The occur- 
rence of ND vaccines that are not potent in 
this study is worrisome as this may be 
contributing to post vaccination failure as 
reported by earlier workers (6,14,17). 
Ramakrishnan et al., (1) and Okwor et al., 
(18) reported a gradual but sharp decline in 
the potency of ND Lasota vaccine when stored 
under conditions of irregular power supply. 
The vaccines that were not potent in this study 




could have been partly caused by storage 
under irregular power supply.  
 Haemagglutination is a measure of the 
ability of a virus to attach to host cells. This is 
used to evaluate potency. Elution is an 
additional observatory phenomenon used to 
measure the weakness of the virus. Newcastle 
disease virus that elute earlier than 30mins is 
usually regarded as weak and therefore not 
capable of initiating immunological reaction. In 
this study, three of the vaccines tested were 





 It is concluded from this study that 
some commercially available ND vaccines in 
Ibadan may not be potent as a result of very 
low HA titer and elution of the vaccine virus. It 
is therefore recommended that potency test 
should be carried out on representative ND 
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